Item 1. FINANCIAL STATEMENTS

179K characters. Original on sec.gov · Markdown

Item 1. FINANCIAL STATEMENTS


The Cigna Group Consolidated Statements of Income
	Unaudited				Unaudited
	Three Months Ended September 30,				Nine Months Ended September 30,
(In millions, except per share amounts)	2025		2024		2025		2024
Revenues
Pharmacy revenues	$	56,054	$	48,284	$	158,336	$	135,421
Premiums	9,081		11,436		30,973		34,493
Fees and other revenues	4,380		3,889		12,412		10,862
Net investment income	233		85		707		696
TOTAL REVENUES	69,748		63,694		202,428		181,472
Benefits and expenses
Pharmacy and other service costs	55,530		47,565		157,196		133,488
Medical costs and other benefit expenses	7,842		9,527		26,089		28,482
Selling, general and administrative expenses	3,362		3,590		11,008		10,979
Amortization of acquired intangible assets	436		436		1,280		1,279
TOTAL BENEFITS AND EXPENSES	67,170		61,118		195,573		174,228
Income from operations	2,578		2,576		6,855		7,244
Interest expense and other	(347)		(376)		(1,046)		(1,073)

Gain (loss) on sale of businesses	38		(87)		79		(106)
Net investment gains (losses)	26		(921)		76		(2,805)
Income before income taxes	2,295		1,192		5,964		3,260
TOTAL INCOME TAXES	322		367		950		1,018
Net income	1,973		825		5,014		2,242
Less: Net income attributable to noncontrolling interests	105		86		291		232
SHAREHOLDERS' NET INCOME	$	1,868	$	739	$	4,723	$	2,010
Shareholders' net income per share
Basic	$	7.02	$	2.65	$	17.65	$	7.13
Diluted	$	6.98	$	2.63	$	17.52	$	7.05

The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.


The Cigna Group Consolidated Statements of Comprehensive Income
	Unaudited				Unaudited
	Three Months Ended September 30,				Nine Months Ended September 30,
(In millions)	2025		2024		2025		2024
Net income	$	1,973	$	825	$	5,014	$	2,242
Other comprehensive income (loss), net of tax
Net unrealized (depreciation) appreciation on securities and derivatives	(401)		264		(180)		493
Net long-duration insurance and contractholder liabilities measurement adjustments	421		(28)		(356)		(800)
Net translation (losses) gains on foreign currencies	(10)		39		68		8
Postretirement benefits liability adjustment	7		4		10		—
Other comprehensive income (loss), net of tax	17		279		(458)		(299)
Total comprehensive income	1,990		1,104		4,556		1,943


Less: Net income attributable to noncontrolling interests	105		86		291		232

SHAREHOLDERS' COMPREHENSIVE INCOME	$	1,885	$	1,018	$	4,265	$	1,711

The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.


The Cigna Group Consolidated Balance Sheets
	Unaudited
	As of September 30,		As of December 31,

(In millions)	2025		2024
Assets
Cash and cash equivalents	$	6,025	$	7,550
Investments	883		665
Accounts receivable, net	31,709		24,227
Inventories	5,632		6,692
Other current assets	2,486		2,732
Assets of businesses held for sale	—		7,004
Total current assets	46,735		48,870
Long-term investments	18,483		15,128
Reinsurance recoverables	4,207		4,378

Property and equipment	3,650		3,654
Goodwill	44,924		44,370
Other intangible assets	28,975		29,417
Other assets	3,389		2,786
Separate account assets	7,556		7,278

TOTAL ASSETS	$	157,919	$	155,881
Liabilities
Current insurance and contractholder liabilities	$	6,018	$	5,388
Pharmacy and other service costs payable	30,301		28,465
Accounts payable	9,346		9,294
Accrued expenses and other liabilities	7,695		9,387
Short-term debt	3,093		3,035
Liabilities of businesses held for sale	—		2,410
Total current liabilities	56,453		57,979
Non-current insurance and contractholder liabilities	10,079		10,254
Deferred tax liabilities, net	6,997		6,975
Other non-current liabilities	3,873		3,215
Long-term debt	30,947		28,937
Separate account liabilities	7,556		7,278

TOTAL LIABILITIES	115,905		114,638
Contingencies — Note 16

Shareholders' equity
Common stock (1)	4		4
Additional paid-in capital	31,698		31,288
Accumulated other comprehensive loss	(2,799)		(2,341)
Retained earnings	47,028		43,519
Less: Treasury stock, at cost	(34,126)		(31,437)
TOTAL SHAREHOLDERS' EQUITY	41,805		41,033
Noncontrolling interests	209		210
Total equity	42,014		41,243
Total liabilities and equity	$	157,919	$	155,881

*(1)*Par value per share, $0.01; shares issued, 404 million as of September 30, 2025 and 403 million as of December 31, 2024; authorized shares, 600 million.

The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.


The Cigna Group
Consolidated Statements of Changes in Total Equity
Unaudited
Three Months Ended September 30, 2025
(In millions)	Common Stock		Additional Paid-in Capital		Accumulated Other Comprehensive (Loss)		Retained Earnings		Treasury Stock		Shareholders' Equity		Noncontrolling Interests		Total Equity		Redeemable Noncontrolling Interests
Balance at June 30, 2025	$	4	$	31,588	$	(2,816)	$	45,564	$	(34,126)	$	40,214	$	216	$	40,430	$	—

Effects of issuing stock for employee benefit plans			110						(3)		107				107
Other comprehensive income					17						17				17		—
Net income							1,868				1,868		105		1,973		—
Common dividends declared (per share: $1.51)							(404)				(404)				(404)
Repurchase of common stock			—						3		3				3
Other transactions impacting noncontrolling interests			—								—		(112)		(112)		—
Balance at September 30, 2025	$	4	$	31,698	$	(2,799)	$	47,028	$	(34,126)	$	41,805	$	209	$	42,014	$	—


Three Months Ended September 30, 2024
(In millions)	Common Stock		Additional Paid-in Capital		Accumulated Other Comprehensive (Loss)		Retained Earnings		Treasury Stock		Shareholders' Equity		Noncontrolling Interests		Total Equity		Redeemable Noncontrolling Interests


Balance at June 30, 2024	$	4	$	31,048	$	(2,442)	$	42,132	$	(29,410)	$	41,332	$	195	$	41,527	$	—
Effect of issuing stock for employee benefit plans			138						(2)		136				136
Other comprehensive income					279						279				279		—
Net income							739				739		86		825		—
Common dividends declared (per share: $1.40)							(391)				(391)				(391)
Repurchase of common stock			—						—		—				—
Other transactions impacting noncontrolling interests			—								—		(78)		(78)		—
Balance at September 30, 2024	$	4	$	31,186	$	(2,163)	$	42,480	$	(29,412)	$	42,095	$	203	$	42,298	$	—

The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.


The Cigna Group
Consolidated Statements of Changes in Total Equity
Unaudited
Nine Months Ended September 30, 2025
(In millions)	Common Stock		Additional Paid-in Capital		Accumulated Other Comprehensive (Loss)		Retained Earnings		Treasury Stock		Shareholders' Equity		Other Non- controlling Interests		Total Equity		Redeemable Noncontrolling Interests


Balance at December 31, 2024	$	4	$	31,288	$	(2,341)	$	43,519	$	(31,437)	$	41,033	$	210	$	41,243	$	—
Effect of issuing stock for employee benefit plans			410						(111)		299				299
Other comprehensive loss					(458)						(458)				(458)		—
Net income							4,723				4,723		291		5,014		—
Common dividends declared (per share: $4.53)							(1,214)				(1,214)				(1,214)
Repurchase of common stock			—						(2,578)		(2,578)				(2,578)
Other transactions impacting noncontrolling interests			—								—		(292)		(292)		—
Balance at September 30, 2025	$	4	$	31,698	$	(2,799)	$	47,028	$	(34,126)	$	41,805	$	209	$	42,014	$	—

Nine Months Ended September 30, 2024
(In millions)	Common Stock		Additional Paid-in Capital		Accumulated Other Comprehensive (Loss)		Retained Earnings		Treasury Stock		Shareholders' Equity		Other Non- controlling Interests		Total Equity		Redeemable Noncontrolling Interests


Balance at December 31, 2023	$	4	$	30,669	$	(1,864)	$	41,652	$	(24,238)	$	46,223	$	21	$	46,244	$	107
Effect of issuing stock for employee benefit plans			517						(117)		400				400
Other comprehensive loss					(299)						(299)				(299)		—
Net income							2,010				2,010		232		2,242		—
Common dividends declared (per share: $4.20)							(1,182)				(1,182)				(1,182)
Repurchase of common stock			—						(5,057)		(5,057)				(5,057)
Other transactions impacting noncontrolling interests			—								—		(50)		(50)		(107)
Balance at September 30, 2024	$	4	$	31,186	$	(2,163)	$	42,480	$	(29,412)	$	42,095	$	203	$	42,298	$	—

The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.

The Cigna Group

Consolidated Statements of Cash Flows


	Unaudited
	Nine Months Ended September 30,

(In millions)	2025		2024
Cash Flows from Operating Activities
Net income	$	5,014	$	2,242
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,053		2,129
Investment (gains) losses, net	(76)		2,805
Deferred income tax benefit	(174)		(351)
(Gain) loss on sale of businesses	(79)		106

Net changes in assets and liabilities, net of non-operating effects:
Accounts receivable, net	(6,911)		(10,600)
Inventories	1,060		577
Reinsurance recoverable and Other assets	(537)		(358)
Insurance liabilities	1,662		(214)
Pharmacy and other service costs payable	1,837		8,979
Accounts payable and Accrued expenses and other liabilities	(857)		(819)
Other, net	460		655
NET CASH PROVIDED BY OPERATING ACTIVITIES	3,452		5,151
Cash Flows from Investing Activities
Proceeds from investments sold:
Debt securities and equity securities	518		569
Investment maturities and repayments:
Debt securities and equity securities	745		585
Commercial mortgage loans	198		79
Other sales, maturities and repayments (primarily short-term and other long-term investments)	656		567
Investments purchased or originated:
Debt securities and equity securities	(5,271)		(943)
Commercial mortgage loans	(117)		(54)
Other (primarily short-term and other long-term investments)	(1,066)		(1,028)
Property and equipment purchases, net	(890)		(1,069)
Acquisitions, net of cash acquired	(597)		(132)
Divestitures, net of cash sold	2,346		—
Renewable energy tax credit equity investments	(485)		(466)
Other, net	(24)		(19)
NET CASH USED IN INVESTING ACTIVITIES	(3,987)		(1,911)
Cash Flows from Financing Activities
Deposits and interest credited to contractholder deposit funds	113		120
Withdrawals and benefit payments from contractholder deposit funds	(201)		(180)
Net change in short-term debt, excluding term loan	(915)		366
Net proceeds on issuance of term loan	1,999		—
Repayment of term loan	(2,000)		—

Repayment of long-term debt	(1,643)		(3,000)
Net proceeds on issuance of long-term debt	4,461		4,462
Repurchase of common stock	(2,620)		(5,012)
Issuance of common stock	178		283
Common stock dividend paid	(1,215)		(1,183)
Other, net	(512)		(255)
NET CASH USED IN FINANCING ACTIVITIES	(2,355)		(4,399)
Effect of foreign currency rate changes on cash, cash equivalents and restricted cash	30		6
Net decrease in cash, cash equivalents and restricted cash	(2,860)		(1,153)
Cash, cash equivalents and restricted cash January 1, (1)	8,931		8,337
Cash, cash equivalents and restricted cash September 30, (1)	6,071		7,184
Cash and cash equivalents reclassified to assets of businesses held for sale	—		(1,249)
Cash, cash equivalents and restricted cash September 30, per Consolidated Balance Sheets (1)	$	6,071	$	5,935
Supplemental Disclosure of Cash Information:
Income taxes paid, net of refunds	$	356	$	839
Interest paid	$	1,043	$	1,037

*(1)*Restricted cash and cash equivalents were reported in other long-term investments and Other assets.

The accompanying Notes to the Consolidated Financial Statements (unaudited) are an integral part of these statements.

THE CIGNA GROUP

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

TABLE OF CONTENTS



Note Number	Footnote	Page

BUSINESS AND CAPITAL STRUCTURE
1	Description of Business	10
2	Summary of Significant Accounting Policies	10
3	Accounts Receivable, Net	11
4	Supplier Finance Program	12

5	Divestiture	12
6	Earnings Per Share	13
7	Debt	14
8	Common and Preferred Stock	15
INSURANCE INFORMATION
9	Insurance and Contractholder Liabilities	15
10	Reinsurance	18
INVESTMENTS
11	Investments	19
12	Fair Value Measurements	22


13	Accumulated Other Comprehensive Income (Loss)	26
WORKFORCE MANAGEMENT AND COMPENSATION
14	Strategic Optimization Program	27





COMPLIANCE, REGULATION AND CONTINGENCIES

15	Income Taxes	27
16	Contingencies and Other Matters	27
RESULTS DETAILS
17	Segment Information	28

Note 1 – Description of Business

The Cigna Group®, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. Powered by our people and our brands, we advance our mission to improve the health and vitality of those we serve.

Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. The majority of these products and services are offered through employers and other entities, such as governmental and nongovernmental organizations, unions and associations. Cigna Healthcare® also offers health and dental insurance products to individuals in the United States and select international markets. In addition to these operations, The Cigna Group also has certain run-off operations.

A full description of our segments follows:

The Evernorth® Health Services reportable segment includes the Pharmacy Benefit Services and the Specialty and Care Services operating segments, which provide independent and coordinated health solutions and capabilities to enable the health care system to work better and help people live healthier lives.

Pharmacy Benefit Services drives high-quality, cost-effective pharmacy care through various services, such as drug claim adjudication, retail pharmacy network administration, benefit design consultation, drug utilization review, drug formulary management and access to our home delivery pharmacy. Specialty and Care Services provides specialty drugs for the treatment of complex and rare diseases, specialty distribution of pharmaceuticals and medical supplies, as well as clinical programs to help our clients drive better whole-person health outcomes through care services.

The Cigna Healthcare reportable segment includes the U.S. Healthcare and International Health operating segments, which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Healthcare provides medical plans and other benefits and solutions for insured and self-insured clients as well as individual health plans. International Health provides health care solutions in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations. U.S. Healthcare also included the Medicare Advantage and related businesses until the divestiture of such businesses to Health Care Services Corporation ("HCSC") on March 19, 2025 (see Note 5 to the Consolidated Financial Statements for further information).

Other Operations comprises the remainder of our business operations, which includes certain continuing (corporate-owned life insurance ("COLI")), run-off and other non-strategic businesses. Our run-off businesses include the (i) variable annuity reinsurance business that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013, (ii) settlement annuity business, and (iii) individual life insurance and annuity and retirement benefits businesses, which were sold through reinsurance agreements.

Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate financing less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs, and eliminations for products and services sold between segments.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain amounts in the Consolidated Statements of Cash Flows have been reclassified to conform to current year presentation and did not have a significant impact on our Consolidated Financial Statements.

Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment, tax and receivable valuations, interest rates, and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.

These interim Consolidated Financial Statements are unaudited but include all adjustments (including normal recurring adjustments) necessary, in the opinion of management, for a fair statement of financial position and results of operations for the periods reported.

The interim Consolidated Financial Statements and Notes should be read in conjunction with the Consolidated Financial Statements and Notes included in the 2024 Annual Report on Form 10-K ("2024 Form 10-K"). The Company has not included certain footnote disclosures that would substantially duplicate the disclosures contained in its 2024 Form 10-K, unless the information in those disclosures materially changed or is required by GAAP. The preparation of interim Consolidated Financial Statements necessarily relies heavily on estimates. This and other factors, including the seasonal nature of portions of the health care and related benefits business, as well as competitive and other market conditions, call for caution in estimating full-year results based on interim results of operations.

Recent Accounting Pronouncements

The Company's 2024 Form 10-K includes discussion of significant recent accounting pronouncements that either have impacted or may impact our financial statements in the future. There are no updates on significant accounting pronouncements recently adopted that have occurred since the Company filed its 2024 Form 10-K. There are no significant accounting pronouncements recently issued and not yet adopted that are expected to impact our operations or financial statements, with the exception of Accounting Standards Update 2025-06, Targeted Improvements to the Accounting for Internal-Use Software.

In September 2025, the Financial Accounting Standards Board issued new guidance related to Targeted Improvements to the Accounting for Internal-Use Software (Subtopic 350-40), Accounting Standards Update ("ASU") 2025-06, which seeks to improve the operability of the recognition guidance considering different methods of software development, mainly more iterative methods. The guidance is required to be adopted January 1, 2028 with early adoption permitted, and transition options include prospective from the date of adoption as well as retrospective adoption. The Company is currently evaluating the impact of this guidance on our results of operations and financial position, as well as potential impacts to systems and controls.

Note 3 – Accounts Receivable, Net

The following amounts were included within Accounts receivable, net:


(In millions)	September 30, 2025		December 31, 2024
Noninsurance customer receivables	$	15,007	$	11,879
Pharmaceutical manufacturers receivables	14,405		10,914
Insurance customer receivables	1,444		3,199
Other receivables	853		162
Total			$	26,154
Accounts receivable, net classified as assets of businesses held for sale			(1,927)
Total	$	31,709	$	24,227

These accounts receivable are reported net of our allowances of $7.0 billion and $5.0 billion as of September 30, 2025 and December 31, 2024, respectively. These allowances include contractual allowances for certain rebates receivable with pharmaceutical manufacturers and certain accounts receivable from third-party payors, discounts and claims adjustments issued to customers in the form of client credits, an allowance for current expected credit losses, and other non-credit adjustments.

The Company's allowance for current expected credit losses was $160 million as of September 30, 2025 and $84 million as of December 31, 2024.

Accounts Receivable Factoring Facility

The Company maintains an uncommitted factoring facility (the "Facility") with a total capacity of $1.5 billion under which certain accounts receivable may be sold on a non-recourse basis to a financial institution. The Facility automatically renewed in July 2025 and is subject to automatic one-year renewal terms unless terminated by either party.

We sold manufacturer accounts receivable under the Facility of $1.3 billion for both the three months ended September 30, 2025 and 2024, respectively, and $4.0 billion and $4.5 billion for the nine months ended September 30, 2025 and 2024, respectively. For the three and nine months ended September 30, 2025 and 2024, factoring fees paid were not material. As of September 30, 2025, there were $0.8 billion of sold accounts receivable that have not been collected from manufacturers and have been removed from the Company's Consolidated Balance Sheets. As of December 31, 2024, all sold accounts receivable had been collected from manufacturers. As of September 30, 2025, all collections from manufacturers have been remitted to the financial institution. As of December 31, 2024, there were $1.0 billion of collections from manufacturers that have not been remitted to the financial institution. Such amounts are recorded within Accrued expenses and other liabilities in the Consolidated Balance Sheets.

Note 4 – Supplier Finance Program

The Company facilitates a voluntary supplier finance program (the "Program") that provides suppliers the opportunity to sell their accounts receivable due from us (i.e., our payment obligations to the suppliers) to a financial institution, on a non-recourse basis, in order to be paid earlier than our payment terms require.

As of both September 30, 2025 and December 31, 2024, $1.6 billion of the Company's outstanding payment obligations were confirmed as valid within the Program by the financial institution and are reflected in Accounts payable in the Consolidated Balance Sheets. The amounts confirmed as valid for both periods are predominately associated with one supplier.

As of September 30, 2025, we have been informed by the financial institution that $606 million of the Company's outstanding payment obligations were voluntarily elected by suppliers to be sold to the financial institution under the Program.

Note 5 – Divestiture

On March 19, 2025, the Company completed the sale of our Medicare Advantage, Medicare Individual Stand-Alone Prescription Drug Plans, Medicare and Other Supplemental Benefits, and CareAllies® businesses (the "Disposal Group" or the "HCSC transaction"). The purchase price increased from $3.3 billion to $4.9 billion, reflecting higher statutory surplus for the legal entities when conveyed to HCSC and post-closing contractual adjustments.

During the three and nine months ended September 30, 2025, the Company recognized a gain of $38 million pre-tax ($241 million after-tax) and $75 million pre-tax ($353 million after-tax), respectively, within Gain (loss) on sale of businesses in the Consolidated Statements of Income. See Note 15 to the Consolidated Financial Statements for discussion of tax matters resulting in an after-tax gain on sale of businesses.

The Company received approximately $4.2 billion cash proceeds at closing. We expect receipt of the remaining approximately $0.6 billion in the fourth quarter of 2025 upon HCSC's collection of amounts due from the Centers for Medicare and Medicaid Services ("CMS") and completion of post-closing contractual adjustments.

The Company determined that the Disposal Group met the criteria to be classified as held for sale and aggregated and classified the assets and liabilities as held for sale in our Consolidated Balance Sheets as of December 31, 2024. The assets and liabilities held for sale as of December 31, 2024 were as follows:


(In millions)	December 31, 2024
Cash and cash equivalents	$	1,339
Investments	1,444
Accounts receivable, net	1,927
Other assets, including Goodwill (1)	2,294
Total assets of businesses held for sale	7,004
Insurance and contractholder liabilities	1,579
All other liabilities	831
Total liabilities of businesses held for sale	$	2,410

(1) Includes Goodwill of $94 million.

Integration and Transaction-Related Costs

In 2025 and 2024, the Company incurred transaction-related costs associated with the HCSC transaction. These costs incurred consisted primarily of certain projects to separate the Company's systems, products and services; fees for legal, advisory and other professional services; and certain employment-related costs. These costs were $7 million pre-tax ($6 million after-tax) for the three months ended and $297 million pre-tax ($226 million after-tax) for the nine months ended September 30, 2025, compared with $77 million pre-tax ($59 million after-tax) for the three months ended and $177 million pre-tax ($135 million after-tax) for the nine months ended September 30, 2024.

Note 6 – Earnings Per Share

Basic and diluted earnings per share were computed as follows:


	Three Months Ended
	September 30, 2025						September 30, 2024
(Shares in thousands, dollars in millions, except per share amounts)	Basic		Effect of Dilution		Diluted		Basic		Effect of Dilution		Diluted
Shareholders' net income	$	1,868			$	1,868	$	739			$	739
Shares:
Weighted average	265,913				265,913		278,457				278,457
Common stock equivalents			1,617		1,617				2,939		2,939
Total shares	265,913		1,617		267,530		278,457		2,939		281,396
Earnings per share	$	7.02	$	(0.04)	$	6.98	$	2.65	$	(0.02)	$	2.63


	Nine Months Ended
	September 30, 2025						September 30, 2024


(Shares in thousands, dollars in millions, except per share amounts)	Basic		Effect of Dilution		Diluted		Basic		Effect of Dilution		Diluted
Shareholders' net income	$	4,723			$	4,723	$	2,010			$	2,010
Shares:
Weighted average	267,635				267,635		282,005				282,005
Common stock equivalents			1,892		1,892				3,037		3,037
Total shares	267,635		1,892		269,527		282,005		3,037		285,042
Earnings per share	$	17.65	$	(0.13)	$	17.52	$	7.13	$	(0.08)	$	7.05

The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive:


	Three Months Ended September 30,		Nine Months Ended September 30,

(In millions)	2025	2024	2025	2024
Anti-dilutive options	2.1	0.8	1.9	1.0

The Company held approximately 137.4 million shares of common stock in treasury as of September 30, 2025, 128.7 million shares as of December 31, 2024 and 122.5 million shares as of September 30, 2024.

Note 7 – Debt

Short-Term and Long-Term Debt. During the nine months ended September 30, 2025, the Company redeemed at par its $700 million 5.685% senior notes that were due March 2026 and repaid $900 million 3.250% senior notes that matured in April 2025. For more information regarding our short-term and long-term debt, see Note 7 of the Company's 2024 Form 10-K.

Debt Issuance. In September 2025, we issued $4.5 billion of new senior notes, as detailed in the table below. The proceeds from this debt issuance were used to repay the $2.0 billion of loans outstanding under the Term Loan Facility as described below. We used the remaining net proceeds for general corporate purposes, including investments and repayment of indebtedness. Interest on this debt is paid semiannually.


Principal	Maturity Date	Interest Rate	Net Proceeds	Redeemable Date(1)	"Make Whole" Premium (2)
$1,000 million	September 15, 2030	4.500%	$994 million	August 15, 2030	15
$1,250 million	September 15, 2032	4.875%	$1,245 million	July 15, 2032	15
$1,500 million	January 15, 2036	5.250%	$1,490 million	October 15, 2035	15
$750 million	January 15, 2056	6.000%	$736 million	July 15, 2055	20

(1) Redeemable at any time prior to this date at a "make whole" premium, defined below. Redeemable at par on or after this date.

(2) "Make whole" premium calculated using a comparable U.S. Treasury rate plus the amount of basis points set forth in this column.

Term Loan. In August 2025, the Company entered into a new 364-day term loan facility (the "Term Loan Facility") and borrowed $2.0 billion to fund an investment in Shields Health Solutions ("Shields"), a leading specialty pharmacy management company. The full outstanding balance was repaid and the Term Loan Facility was terminated in September 2025, using proceeds from the debt issuance described above.

Revolving Credit Agreement. Our Credit Agreement (defined below) provides us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. As of September 30, 2025, there was no outstanding balance under the Credit Agreement.

In April 2025, the Company replaced its previous revolving credit agreements and entered into a $6.5 billion, five-year revolving credit and letter of credit agreement that will mature in April 2030, with an option to extend the maturity date for additional one-year periods, subject to consent of the banks (the "Credit Agreement"). The Company can borrow up to $6.5 billion under the Credit Agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit.

The Credit Agreement includes an option to increase commitments up to $1.5 billion for a maximum total commitment of $8.0 billion. The Credit Agreement allows for borrowings at either a base rate, term Secured Overnight Financing Rate ("SOFR") or daily simple SOFR plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings.

The Credit Agreement also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreement, may not exceed 60%, subject to certain exceptions upon the consummation of an acquisition.

Commercial Paper. Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $6.5 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. There was no commercial paper balance as of September 30, 2025.

Debt Covenants. The Company was in compliance with its debt covenants as of September 30, 2025.

Interest Expense. Interest expense on long-term and short-term debt was $363 million for the three months ended and $1.1 billion for the nine months ended September 30, 2025, compared with $380 million for the three months ended and $1.1 billion for the nine months ended September 30, 2024.

Note 8 – Common and Preferred Stock

Dividends

The following table provides details of the Company's dividend payments:


Record Date	Payment Date	Amount per Share	Total Amount Paid (in millions)
2025
March 5, 2025	March 20, 2025	$1.51	$412
June 3, 2025	June 18, 2025	$1.51	$401
September 4, 2025	September 18, 2025	$1.51	$402

2024
March 6, 2024	March 21, 2024	$1.40	$401
June 4, 2024	June 20, 2024	$1.40	$392
September 4, 2024	September 19, 2024	$1.40	$390

On October 22, 2025, the Board of Directors of The Cigna Group (the "Board") declared the fourth quarter cash dividend of $1.51 per share of The Cigna Group common stock to be paid on December 18, 2025 to shareholders of record on December 4, 2025. The Company currently intends to pay regular quarterly dividends, with future declarations subject to approval by the Board and the Board's determination that the declaration of dividends remains in the best interests of The Cigna Group and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company's financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board may deem relevant.

Note 9 – Insurance and Contractholder Liabilities

**A.**Account Balances – Insurance and Contractholder Liabilities

The Company's insurance and contractholder liabilities were comprised of the following:


	September 30, 2025						December 31, 2024						September 30, 2024
(In millions)	Current		Non-current		Total		Current		Non-current		Total		Total
Unpaid claims and claim expenses
Cigna Healthcare	$	4,616	$	60	$	4,676	$	4,932	$	86	$	5,018	$	5,088
Other	155		180		335		147		144		291		312
Future policy benefits
Cigna Healthcare	38		154		192		91		507		598		599
Other Operations	142		3,155		3,297		157		3,140		3,297		3,458
Contractholder deposit funds
Cigna Healthcare	—		—		—		9		115		124		130
Other Operations	331		5,801		6,132		366		5,958		6,324		6,346
Market risk benefits	22		687		709		25		760		785		944
Unearned premiums	714		42		756		753		31		784		741
Total							6,480		10,741		17,221		17,618
Insurance and contractholder liabilities classified as liabilities of businesses held for sale (1)							(1,092)		(487)		(1,579)		(1,568)
Total insurance and contractholder liabilities	$	6,018	$	10,079	$	16,097	$	5,388	$	10,254	$	15,642	$	16,050

(1) Amounts classified as liabilities of businesses held for sale include $983 million of Unpaid claims, $408 million of Future policy benefits, $85 million of Unearned premiums and $103 million of Contractholder deposit funds as of December 31, 2024 and $937 million of Unpaid claims, $422 million of Future policy benefits, $98 million of Unearned premiums and $111 million of Contractholder deposit funds as of September 30, 2024.

Insurance and contractholder liabilities expected to be paid within one year are classified as current.

**B.**Unpaid Claims and Claim Expenses – Cigna Healthcare

This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, expected development on reported claims, claims that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities.

The total of incurred but not reported liabilities plus expected development on reported claims and reported claims in process was $4.5 billion as of September 30, 2025 and $4.7 billion as of September 30, 2024. The decrease was driven by the HCSC transaction, partially offset by an increase in stop loss reserves primarily due to seasonality.

Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows:


	Nine Months Ended September 30,
(In millions)	2025 (1)		2024 (1)
Beginning balance	$	5,018	$	5,092
Less: Reinsurance and other amounts recoverable	159		236
Beginning balance, net	4,859		4,856

Incurred costs related to:
Current year	25,763		28,314
Prior years	(319)		(422)
Total incurred	25,444		27,892
Paid costs related to:
Current year	20,399		23,761
Prior years	4,055		4,059
Total paid	24,454		27,820
Less: Divestiture and other	1,323		—
Ending balance, net	4,526		4,928
Add: Reinsurance and other amounts recoverable	150		160
Ending balance	$	4,676	$	5,088

(1) Includes unpaid claims amounts classified as liabilities of businesses held for sale prior to the completion of the HCSC transaction. As of December 31, 2024, September 30, 2024 and December 31, 2023, includes $983 million, $937 million and $823 million, respectively, classified as liabilities of businesses held for sale.

Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 to the Consolidated Financial Statements for additional information on reinsurance.

Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows:


	Nine Months Ended September 30,
	2025				2024
(Dollars in millions)	$		% (1)		$		% (2)
Actual completion factors and other	$	185	0.5	%	$	212	0.6	%
Medical cost trend	134		0.3		210		0.6

Total favorable variance	$	319	0.8	%	$	422	1.2	%

*(1)*Percentage of current year incurred costs as reported for the year ended December 31, 2024.

*(2)*Percentage of current year incurred costs as reported for the year ended December 31, 2023.

Favorable prior year development in both years primarily reflects lower than expected utilization of medical services as compared to our assumptions.

**C.**Future Policy Benefits

Cigna Healthcare

Future policy benefits for the Cigna Healthcare segment were primarily related to the businesses divested to HCSC on March 19, 2025. Excluding the divestiture, changes in the future policy benefits for the nine months ended September 30, 2025 and September 30, 2024 were not material.

Other Operations

The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows:


	As of
	September 30, 2025		September 30, 2024
Interest accretion rate	5.64	%	5.64	%
Current discount rate	5.11	%	4.81	%
Weighted average duration	10.8 years		11.3 years

Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations' traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate, and the remaining amortizable deferred profit liability.

Future policy benefits for Other Operations include deferred profit liability of $0.4 billion as of both September 30, 2025 and September 30, 2024. Future policy benefits excluding deferred profit liability were $2.9 billion as of both September 30, 2025 and December 31, 2024, $3.1 billion as of September 30, 2024, and $3.2 billion as of December 31, 2023. Undiscounted expected future policy benefits were $4.2 billion as of September 30, 2025 and $4.3 billion as of September 30, 2024. As of both September 30, 2025 and September 30, 2024, $0.9 billion of the future policy benefit reserve was recoverable through treaties with external reinsurers.

**D.**Contractholder Deposit Funds

Contractholder deposit fund liabilities within Other Operations were $6.1 billion as of September 30, 2025, $6.3 billion as of December 31, 2024, $6.3 billion as of September 30, 2024 and $6.5 billion as of December 31, 2023. Approximately 37% of the balance is reinsured externally. Activity in these liabilities is presented net of reinsurance in the Consolidated Statements of Cash Flows. Changes in contractholder deposit fund liabilities generally relates to withdrawals and benefit payments, partially offset by deposits and interest credited.

As of September 30, 2025, the weighted average crediting rate, net amount at risk and cash surrender value for contractholder deposit fund liabilities not effectively exited through reinsurance were 3.26%, $2.6 billion and $2.8 billion, respectively. The comparative amounts as of September 30, 2024 were 3.33%, $2.9 billion and $2.8 billion, respectively. More than 99% of the $3.9 billion liability as of September 30, 2025 and the $4.0 billion liability as of September 30, 2024 not reinsured externally is for contracts with guaranteed interest rates of 3% - 4%, and approximately $1.2 billion and $1.1 billion, respectively, represented contracts with policies at the guarantee. At these same period ends, $1.1 billion and $1.2 billion was 50 - 150 basis points ("bps") above the guarantee, and the remaining $1.6 billion as of September 30, 2025 and $1.7 billion as of September 30, 2024 represented contracts above the guarantee that pay the policyholder based on the greater of a guaranteed minimum cash value or the actual cash value. As of both September 30, 2025 and September 30, 2024, more than 90% of these contracts have actual cash values of at least 110% of the guaranteed cash value.

**E.**Market Risk Benefits

Liabilities for market risk benefits ("MRBs") consist of variable annuity reinsurance contracts in Other Operations. These liabilities arise under annuities and riders to annuities written by ceding companies that guarantee the benefit received at death and, for a subset of policies, also provide contractholders the option, within 30 days of a policy anniversary after the appropriate waiting period, to elect minimum income payments. The Company's capital market risk exposure on variable annuity reinsurance contracts arises when the reinsured guaranteed minimum benefit exceeds the contractholder's account value in the related underlying mutual funds at the time the insurance benefit is payable under the respective contract. The Company receives and pays premium periodically based on the terms of the reinsurance agreements.

Market risk benefits activity was as follows:


	Nine Months Ended September 30,
(In millions)	2025		2024
Balance, beginning of year	$	785	$	1,003
Balance, beginning of year, before the effect of nonperformance risk (own credit risk)	838		1,085
Changes due to expected run-off	(14)		(7)
Changes due to capital markets versus expected	(30)		(78)
Changes due to policyholder behavior versus expected	(20)		(26)
Assumption changes	(17)		37
Balance, end of period, before the effect of changes in nonperformance risk (own credit risk)	757		1,011
Nonperformance risk (own credit risk), end of period	(48)		(67)
Balance, end of period	$	709	$	944
Reinsured market risk benefit, end of period	$	756	$	1,008

The following table presents the net amount at risk and the average attained age of contractholders (weighted by exposure) for contracts assumed by the Company. The net amount at risk is the amount the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded, as discussed further in Note 10 to the Consolidated Financial Statements.


(Dollars in millions, excludes impact of reinsurance ceded)	September 30, 2025		September 30, 2024
Net amount at risk	$	1,141	$	1,361
Average attained age of contractholders (weighted by exposure)	78.2 years		77.6 years

Note 10 – Reinsurance

The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.

The majority of the Company's reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting company was not acquired. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. The Company reviews its reinsurance arrangements and establishes reserves against the recoverables primarily for expected credit losses.

The Company's reinsurance recoverables as of September 30, 2025 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value:


(In millions)	Fair Value of Collateral Contractually Required to Meet or Exceed Carrying Value of Recoverable		Collateral Provisions Exist That May Mitigate Risk of Credit Loss (1)		No Collateral		Total
Ongoing operations
A- equivalent and higher current ratings (2)	$	—	$	6	$	227	$	233
BBB- to BBB+ equivalent current credit ratings (2)	—		—		64		64
Not rated	85		7		3		95
Acquisition, disposition or run-off activities
BBB+ equivalent and higher current ratings (2)(3)	293		2,847		74		3,214

Not rated	—		6		1		7
Total reinsurance recoverables before market risk benefits	$	378	$	2,866	$	369	$	3,613
Allowance for uncollectible reinsurance							(23)
Market risk benefits							756
Total reinsurance recoverables (4)							$	4,346

*(1)*Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level.

*(2)*Certified by a nationally recognized statistical ratings organization ("NRSRO").

*(3)*Comprised of six reinsurers, of which 75% is held by two reinsurers, Lincoln National Life Insurance Company and Lincoln Life and Annuity Company of New York.

*(4)*Includes $139 million of current reinsurance recoverables that are reported in Other current assets.

The Company entered into an agreement with Berkshire to effectively exit the variable annuity reinsurance business via a reinsurance transaction in 2013. Variable annuity contracts are accounted for as assumed and ceded reinsurance and categorized as market risk benefits as discussed in Note 9 to the Consolidated Financial Statements. Berkshire reinsured 100% of the Company's future cash flows in this business, net of other reinsurance arrangements existing at that time. The reinsurance agreement is subject to an overall limit, with approximately $3.0 billion remaining as of September 30, 2025. As a result of the reinsurance transaction, amounts payable are offset by a corresponding reinsurance recoverable, provided the increased recoverable remains within the overall Berkshire limit. As of both September 30, 2025 and 2024, market risk benefits (shown in the table net of nonperformance risk as of September 30, 2025) were predominantly reinsured by Berkshire, which is rated AA+ by an NRSRO. As of September 30, 2025, approximately 100% of the Berkshire recoverable is secured by assets in a trust.

Note 11 – Investments

The following table summarizes the Company's investments by category and current or long-term classification:


	September 30, 2025						December 31, 2024
(In millions)	Current		Long-Term		Total		Current		Long-Term		Total
Debt securities	$	490	$	7,861	$	8,351	$	463	$	8,960	$	9,423
Equity securities	17		3,500		3,517		7		554		561
Commercial mortgage loans	100		1,158		1,258		108		1,243		1,351
Policy loans	—		1,080		1,080		—		1,156		1,156
Other long-term investments	—		4,884		4,884		—		4,576		4,576
Short-term investments	276		—		276		170		—		170
Total							$	748	$	16,489	$	17,237
Investments classified as assets of businesses held for sale (1)							(83)		(1,361)		(1,444)
Investments per Consolidated Balance Sheets	$	883	$	18,483	$	19,366	$	665	$	15,128	$	15,793

(1) Investments related to the HCSC transaction that were held for sale as of December 31, 2024. These investments were primarily comprised of debt securities.

**A.**Investment Portfolio

Debt Securities

The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of September 30, 2025:



(In millions)	Amortized Cost		Fair Value
Due in one year or less	$	653	$	573
Due after one year through five years	3,649		3,639
Due after five years through ten years	2,103		2,052
Due after ten years	1,978		1,842
Mortgage and other asset-backed securities	271		245
Total	$	8,654	$	8,351

Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties.

Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below:


(In millions)	Amortized Cost		Allowance for Credit Loss		Unrealized Appreciation		Unrealized Depreciation		Fair Value
September 30, 2025
Federal government and agency	$	214	$	—	$	16	$	(4)	$	226
State and local government	24		—		1		—		25
Foreign government	407		—		12		(7)		412
Corporate	7,738		(118)		168		(345)		7,443
Mortgage and other asset-backed	271		—		2		(28)		245
Total	$	8,654	$	(118)	$	199	$	(384)	$	8,351


December 31, 2024
Federal government and agency	$	276	$	—	$	14	$	(9)	$	281
State and local government	37		—		1		(1)		37
Foreign government	350		—		5		(11)		344
Corporate	9,091		(111)		102		(659)		8,423
Mortgage and other asset-backed	371		—		1		(34)		338
Total	$	10,125	$	(111)	$	123	$	(714)	$	9,423

Review of Declines in Fair Value. Management reviews debt securities in an unrealized loss position to determine whether a credit loss allowance is needed based on criteria that include severity of decline; financial health and specific prospects of the issuer; and changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.

The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded (by investment grade and the length of time these securities have been in an unrealized loss position). Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased.


	September 30, 2025							December 31, 2024
(Dollars in millions)	Fair Value		Amortized Cost		Unrealized Depreciation		Number of Issues	Fair Value		Amortized Cost		Unrealized Depreciation		Number of Issues
One year or less
Investment grade	$	276	$	278	$	(2)	121	$	1,203	$	1,227	$	(24)	545
Below investment grade	52		58		(6)		252	245		250		(5)		739
More than one year
Investment grade	3,389		3,747		(358)		918	4,687		5,319		(632)		1,297
Below investment grade	213		231		(18)		74	416		469		(53)		123
Total	$	3,930	$	4,314	$	(384)	1,365	$	6,551	$	7,265	$	(714)	2,704

Equity Securities

The following table provides the values of the Company's equity security investments:


	September 30, 2025				December 31, 2024
(In millions)	Cost		Carrying Value		Cost		Carrying Value
Equity securities with readily determinable fair values	$	641	$	134	$	635	$	37
Equity securities with no readily determinable fair value	6,167		3,383		3,215		524
Total	$	6,808	$	3,517	$	3,850	$	561

In the third quarter of 2025, the Company invested $3.5 billion in preferred stock of Shields and a compounding dividend is recorded in Fees and other revenues within the Consolidated Statements of Income. The investment is included in equity securities with no readily determinable fair value in the table above.

Commercial Mortgage Loans

Mortgage loans held by the Company are made exclusively to commercial borrowers and are diversified by property type, location and borrower. Loans are generally issued at fixed rates of interest and are secured by high-quality, primarily completed and substantially leased operating properties.

The Company regularly evaluates and monitors credit risk from the initial mortgage loan underwriting and throughout the investment holding period. The annual portfolio review performed in the second quarter of 2025 confirmed ongoing strong overall credit quality in line with the previous year's results. For more information on the Company's accounting policies and methodologies regarding these investments, see Note 11 in the Company's 2024 Form 10-K.

The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio:


(Dollars in millions)	September 30, 2025					December 31, 2024
Loan-to-Value Ratio	Carrying Value		Average Debt Service Coverage Ratio	Average Loan-to-Value Ratio		Carrying Value		Average Debt Service Coverage Ratio	Average Loan-to-Value Ratio
Below 60%	$	356	2.13			$	547	2.07
60% to 79%	717		1.77			595		1.83
80% to 100%	185		0.87			209		0.51



Total	$	1,258	1.72	71	%	$	1,351	1.70	69	%

Other Long-Term Investments

Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one-quarter lag due to the timing of when financial information is received from the general partner or manager of the investments.

Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flow estimates indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other. The following table provides the carrying value information for these investments:


	Carrying Value as of
(In millions)	September 30, 2025		December 31, 2024
Real estate investments	$	1,800	$	1,763
Securities partnerships	2,896		2,587
Other	188		226
Total	$	4,884	$	4,576

**B.**Derivative Financial Instruments

The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt. The Company also has derivative instruments associated with certain equity securities; see Note 12 to the Consolidated Financial Statements for further discussion.

As of September 30, 2025, the notional value of interest rate swap contracts increased to $2.8 billion compared with $2.7 billion as of December 31, 2024. There were no other material changes to the Company's individual derivative hedging strategies during the three and nine months ended September 30, 2025. Please refer to the Company's 2024 Form 10-K for further discussion of the types of derivative financial instruments and associated accounting policies. The effects of derivative financial instruments used in our individual hedging strategies were not material to the Consolidated Financial Statements as of September 30, 2025 and December 31, 2024. The gross fair values of our derivative financial instruments are presented in Note 12 to the Consolidated Financial Statements.

**C.**Investment Gains and Losses

Net investment gains (losses), before income taxes were $26 million and $76 million, respectively, for the three and nine months ended September 30, 2025, versus $(921) million and $(2,805) million, respectively, for the three and nine months ended September 30, 2024. Net investment results for the three and nine months ended September 30, 2025 increased, reflecting the absence of the impairment of equity securities recorded in 2024. These amounts exclude investment gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders.

Note 12 – Fair Value Measurements

For a description of the policies, methods and assumptions that are used to estimate fair value and determine the fair value hierarchy for each class of financial instruments, see Note 12 in the Company's 2024 Form 10-K.

**A.**Financial Assets and Financial Liabilities Carried at Fair Value

The following table provides information about the Company's investment and derivative financial assets and liabilities carried at fair value on a recurring basis. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements in the Company's 2024 Form 10-K. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders.


(In millions)	Quoted Prices in Active Markets for Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)				Total
	September 30, 2025		December 31, 2024		September 30, 2025		December 31, 2024		September 30, 2025		December 31, 2024		September 30, 2025		December 31, 2024
Financial assets at fair value
Debt securities
Federal government and agency	$	105	$	165	$	121	$	116	$	—	$	—	$	226	$	281
State and local government	—		—		25		37		—		—		25		37
Foreign government	—		—		412		344		—		—		412		344
Corporate	—		—		7,130		8,049		313		374		7,443		8,423
Mortgage and other asset-backed	—		—		207		295		38		43		245		338
Total debt securities	105		165		7,895		8,841		351		417		8,351		9,423
Equity securities (1)	76		1		46		36		12		—		134		37
Short-term investments	—		—		276		170		—		—		276		170
Derivative assets	—		—		74		168		936		—		1,010		168
Financial liabilities at fair value
Derivative liabilities	$	—	$	—	$	20	$	1	$	320	$	—	$	340	$	1

*(1)*Excludes certain equity securities that have no readily determinable fair value.

Level 3 Financial Assets and Financial Liabilities

Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9E in the Company's 2024 Form 10-K, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy.

Information about Debt Securities

The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security.

The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. An increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement.


	Fair Value as of					Unobservable Adjustment Range (Weighted Average by Quantity) as of
(Fair value in millions)	September 30, 2025		December 31, 2024		Unobservable Input September 30, 2025	September 30, 2025		December 31, 2024
Debt securities
Corporate	$	312	$	373	Liquidity	60 - 2360 (400)	bps	60 - 1520 (370)	bps
Mortgage and other asset-backed securities	38		43		Liquidity	120 - 500 (290)	bps	100 - 550 (280)	bps
Other debt securities	1		1
Total Level 3 debt securities	$	351	$	417

Information about Derivative Instruments

Derivative Instruments associated with certain equity securities are valued each reporting period using a Monte Carlo simulation and estimated business enterprise value and are recorded in Other assets and Other non-current liabilities in the Consolidated Balance Sheets. The significant unobservable Level 3 measurement inputs used are forecasted earnings measures and equity as well as adjustments to reflect estimated volatility and credit spreads. See Note 11A to the Consolidated Financial Statements for further information.

Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value

The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs.



	Three Months Ended September 30,				Nine Months Ended September 30,
(In millions)	2025		2024		2025		2024

Beginning balance	$	362	$	397	$	417	$	447
Losses included in Shareholders' net income	(9)		(10)		(23)		(71)
Gains included in Other comprehensive income (loss)	21		8		31		3

Purchases, sales and settlements
Purchases	617		4		644		15
Sales	(1)		(2)		(3)		(2)
Settlements	(21)		(4)		(101)		(19)
Total purchases, sales and settlements	595		(2)		540		(6)
Transfers into / (out of) Level 3
Transfers into Level 3	10		32		59		63
Transfers out of Level 3	—		(2)		(45)		(13)
Total transfers into / (out of) Level 3	10		30		14		50
Ending balance	$	979	$	423	$	979	$	423
Total losses included in Shareholders' net income attributable to instruments held at the reporting date	$	(6)	$	(9)	$	(23)	$	(71)
Change in unrealized gain or (loss) included in Other comprehensive income (loss) for assets held at the end of the reporting period	$	11	$	8	$	18	$	3

Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net investment gains (losses) and Net investment income. Gains and losses included in Other comprehensive income (loss), net of tax, in the tables above are reflected in Net unrealized (depreciation) appreciation on securities and derivatives in the Consolidated Statements of Comprehensive Income.

Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty, and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads. Transfers between Level 2 and Level 3 during 2025 and 2024 primarily reflected changes in liquidity estimates for certain private placement issuers across several sectors. See discussion under Level 3 Financial Assets and Financial Liabilities above for more information.

Separate Accounts

The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. The separate account activity for the nine months ended September 30, 2025 and 2024 was primarily driven by changes in the market values of the underlying separate account investments.

Fair values of Separate account assets were as follows:


	Quoted Prices in Active Markets for Identical Assets (Level 1)				Significant Other Observable Inputs (Level 2)				Significant Unobservable Inputs (Level 3)				Total
(In millions)	September 30, 2025		December 31, 2024		September 30, 2025		December 31, 2024		September 30, 2025		December 31, 2024		September 30, 2025		December 31, 2024
Guaranteed separate accounts (See Note 16)	$	248	$	231	$	333	$	345	$	—	$	—	$	581	$	576
Non-guaranteed separate accounts (1)	274		267		5,809		5,575		213		228		6,296		6,070
Subtotal	$	522	$	498	$	6,142	$	5,920	$	213	$	228	6,877		6,646
Non-guaranteed separate accounts priced at net asset value as a practical expedient (1)													656		632
Total													$	7,533	$	7,278

*(1)*Non-guaranteed separate accounts include $3.8 billion as of both September 30, 2025 and December 31, 2024 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of both September 30, 2025 and December 31, 2024. Non-guaranteed separate accounts are primarily comprised of securities partnerships, real estate and real estate funds.

Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly issued, privately placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the three and nine months ended September 30, 2025 or 2024.

**B.**Assets and Liabilities Measured at Fair Value under Certain Conditions

Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value.

For the nine months ended September 30, 2025, impairments recognized requiring the assets and liabilities described above to be measured at fair value were not material. For the nine months ended September 30, 2024, we determined our investment in VillageMD was fully impaired and recorded a $2.7 billion loss in Net investment gains (losses) in the Company's Consolidated Statements of Income. Observable price changes for equity securities with no readily determinable fair value were not material for the nine months ended September 30, 2025 or September 30, 2024.

**C.**Fair Value Disclosures for Financial Instruments Not Carried at Fair Value

The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table.


	Classification in Fair Value Hierarchy		September 30, 2025						December 31, 2024
(In millions)		Fair Value			Carrying Value			Fair Value			Carrying Value
Commercial mortgage loans	Level 3		$	1,214		$	1,258		$	1,256		$	1,351
Long-term debt, including current maturities, excluding finance leases	Level 2		$	32,378		$	33,923		$	28,392		$	31,008

Note 13 – Accumulated Other Comprehensive Income (Loss)

Accumulated Other Comprehensive Income (Loss) ("AOCI") includes net unrealized (depreciation) appreciation on securities and derivatives, change in discount rate and instrument-specific credit risk for certain long-duration insurance contractholder liabilities (see Note 9 to the Consolidated Financial Statements), foreign currency translation, and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized.

Shareholders' other comprehensive loss, net of tax, for the three and nine months ended September 30, 2025 and September 30, 2024 is primarily attributable to the change in discount rates for certain long-duration liabilities and unrealized changes in the market values of securities and derivatives, including the impacts from unconsolidated entities reported on the equity method.

Changes in the components of AOCI were as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(In millions)	2025		2024		2025		2024
Securities and derivatives


Beginning balance	$	1,053	$	400	$	832	$	171

Unrealized (depreciation) appreciation on securities and derivatives, before reclassification, net of tax benefit (expense) of $137, $(65), $93 and $(133), respectively	(406)		254		(237)		435


Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(1), $(2), $(14) and $(15), respectively	5		10		57		58

Other comprehensive (loss) income, net of tax	(401)		264		(180)		493
Ending balance	$	652	$	664	$	652	$	664
Net long-duration insurance and contractholder liabilities measurement adjustments


Beginning balance	$	(2,815)	$	(1,743)	$	(2,038)	$	(971)

Net current period change in discount rate for certain long-duration liabilities, before reclassification, net of tax (expense) benefit of $(146), $3, $92 and $265, respectively	427		(31)		(296)		(789)


Amounts reclassified to Shareholders' net income, net of tax expense of $—, $—, $16 and $—, respectively	—		—		(56)		—


Net current period change in discount rate for certain long-duration liabilities, net of tax (expense) benefit of $(146), $3, $108 and $265, respectively	427		(31)		(352)		(789)


Net current period change in instrument-specific credit risk for market risk benefits, net of tax benefit of $2, $—, $1 and $4, respectively	(6)		3		(4)		(11)

Other comprehensive income (loss), net of tax	421		(28)		(356)		(800)
Ending balance	$	(2,394)	$	(1,771)	$	(2,394)	$	(1,771)
Translation of foreign currencies


Beginning balance	$	(120)	$	(180)	$	(198)	$	(149)

Net translation of foreign currencies, before reclassification, net of tax (expense) of $—, $(2), $(8) and $(5), respectively	(10)		39		68		8







Ending balance	$	(130)	$	(141)	$	(130)	$	(141)
Postretirement benefits liability
Beginning balance	$	(934)	$	(919)	$	(937)	$	(915)

Amounts reclassified to Shareholders' net income, net of tax (benefit) of $(3), $(5), $(7) and $(8), respectively	7		4		19		16


Net change due to valuation update, before reclassification, net of tax benefit of $1, $1, $4 and $5, respectively	—		—		(9)		(16)

Other comprehensive income, net of tax	7		4		10		—
Ending balance	$	(927)	$	(915)	$	(927)	$	(915)
Total Accumulated other comprehensive loss


Beginning balance	$	(2,816)	$	(2,442)	$	(2,341)	$	(1,864)

Shareholders' other comprehensive income (loss), net of tax (expense) benefit of $(10), $(70), $177 and $113, respectively	17		279		(458)		(299)

Ending balance	$	(2,799)	$	(2,163)	$	(2,799)	$	(2,163)

Note 14 – Strategic Optimization Program

In the first quarter of 2025, the Company commenced an enterprise-wide initiative to evolve our business and deliver a more efficient and improved experience for our patients, providers and customers. This program is expected to continue through December 2026 and includes severance and other employee costs, asset impairments and accelerated asset amortization, and the operating results of certain small non-strategic businesses that we plan to discontinue. As we continue to evaluate additional opportunities to improve the overall efficiency and effectiveness of our operations, we anticipate future charges.

During the three and nine months ended September 30, 2025, we reported total costs of $222 million pre-tax ($168 million after-tax) and $566 million pre-tax ($429 million after-tax), respectively, associated with this initiative. During the three and nine months ended September 30, 2025, the total costs included a charge in Selling, general and administrative ("SG&A") expenses of $181 million, pre-tax and $467 million, pre-tax, respectively, that was primarily associated with employee severance. The remainder for both periods reflects the operating results of certain non-strategic businesses. We expect substantially all of the accrued liability to be paid by the end of 2026. See Note 17 to the Consolidated Financial Statements for further details of the strategic optimization program impact by segment.

The following table summarizes a roll forward of the accrued liability recorded in Accrued expenses and other liabilities during the nine months ended September 30, 2025:


(In millions)



Balance, December 31, 2024	$	—
2025 charges	335
2025 payments	(171)
Balance, September 30, 2025	$	164

Note 15 – Income Taxes

Income Tax Expense

The effective tax rates of 14.0% and 15.9% for the three and nine months ended September 30, 2025, respectively, were lower than the effective tax rates of 30.8% and 31.2% for the three and nine months ended September 30, 2024, respectively. The decrease in the three and nine months comparative rates was primarily due to the absence of a valuation allowance related to the impairment of equity securities in 2024, partially offset by the absence of tax benefits recorded in 2024 related to the release of tax reserves following favorable state audit resolutions.

During the three months ended September 30, 2025, the reallocation of the HCSC transaction purchase price by legal entity resulted in an equal write-off of the deferred tax asset ("DTA") and valuation allowance associated with the tax-deductible capital loss on the sale, resulting in zero net impact on the Company's total tax provision. Additionally, the decrease in valuation allowance associated with the tax-deductible capital loss on the sale recorded in the three months ended September 30, 2025 generated a substantial portion of the after-tax gain on sale discussed in Note 5 to the Consolidated Financial Statements. This valuation allowance decrease was offset by an increase in valuation allowance associated with DTAs on the impairment of equity securities, as discussed below. As such, there was no material change to the realizability assessment of the Company's consolidated DTAs and no material net impact to the Company's consolidated tax expense. We continue to monitor and evaluate the need for any additional valuation allowance.

As of September 30, 2025, we had approximately $824 million in DTAs associated with the impairment of equity securities as well as unrealized investment losses. A valuation allowance of $788 million and $635 million as of the nine months ended September 30, 2025 and September 30, 2024, respectively, primarily relates to the impairment of equity securities discussed in Note 11 to the Consolidated Financial Statements. The increase in valuation allowance primarily associated with the impairment of equity securities resulted from the reallocation of available sources of capital income, as discussed above.

Note 16 – Contingencies and Other Matters

The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business.

**A.**Financial Guarantees: Retiree and Life Insurance Benefits

The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets

to provide for benefit payments. As of September 30, 2025, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $400 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of September 30, 2025. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.

The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition.

**B.**Certain Other Guarantees

The Company had indemnification obligations as of September 30, 2025 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with laws or regulations, or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a stated dollar amount or a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no recorded liabilities for these indemnification obligations as of September 30, 2025.

**C.**Guaranty Fund Assessments

The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions. There were no material charges or credits resulting from existing or new guaranty fund assessments for the nine months ended September 30, 2025.

**D.**Legal and Regulatory Matters

The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a qui tam relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health services business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising from audits by the Internal Revenue Service or other state and foreign jurisdictions, including those resulting in litigation, are accounted for under GAAP guidance for uncertain tax positions.

Note 17 – Segment Information

See Note 1 to the Consolidated Financial Statements for a description of our segments. A description of our basis for reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The Chairman and Chief Executive Officer is the chief operating decision maker ("CODM") responsible for making decisions about resources to be allocated to the segment and assessing its performance.

The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management, including the CODM, believes these metrics reflect the underlying results of business operations and facilitate analysis of trends in underlying revenue, expenses and profitability to enable resource allocation decisions. We define pre-tax adjusted income (loss) from operations as income (loss) before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net investment gains/losses, amortization of acquired intangible assets and special items. The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management, including the CODM, believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results.

The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management, including the CODM, believes are not representative of the underlying results

of operations due to their nature or size. We exclude these items from this measure because management, including the CODM, believes they are not indicative of past or future underlying performance of the business.

The Company does not report total assets by segment because this is not a metric used by the CODM to allocate resources or evaluate segment performance.

The following table presents the special items charges (benefits) recorded by the Company, as well as the respective financial statement line items impacted:


	Three Months Ended September 30,								Nine Months Ended September 30,
	2025				2024				2025				2024
(In millions)	Pre-tax		After-tax		Pre-tax		After-tax		Pre-tax		After-tax		Pre-tax		After-tax
Strategic optimization program (primarily Selling, general and administrative expenses)	$	222	$	168	$	—	$	—	$	566	$	429	$	—	$	—
Integration and transaction-related costs (Selling, general and administrative expenses)	7		6		77		59		297		226		177		135
(Gain) loss on sale of businesses	(38)		(241)		87		62		(79)		(356)		106		19
(Benefits) associated with litigation matters (Selling, general and administrative expenses)	(17)		(13)		—		—		(17)		(13)		—		—
Deferred tax expenses, net (Income taxes, less amount attributable to noncontrolling interests)	—		19		—		41		—		53		—		75
Impairment of dividend receivable (Net investment income)	—		—		182		138		—		—		182		138


Total impact from special items	$	174	$	(61)	$	346	$	300	$	767	$	339	$	465	$	367

Summarized segment financial information was as follows:


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
Three months ended September 30, 2025
Revenues from external customers	$	59,982	$	9,460	$	68	$	5	$	69,515
Intersegment revenues	380		1,357		14		(1,751)
Net investment income	29		116		80		8		233
Total revenues	60,391		10,933		162		(1,738)		69,748
Net investment results from certain equity method investments	—		(178)		—		—		(178)

Adjusted revenues	$	60,391	$	10,755	$	162	$	(1,738)	$	69,570
Pharmacy and other service costs	57,326		—
Medical costs	—		7,579
Selling, general and administrative expenses excluding special items	1,037		2,140
Other segment items (1)
Interest (expense) and other	(2)		2
Less: Income attributable to noncontrolling interests	123		—
Pre-tax adjusted income (loss) from operations	1,903		1,038		36		(399)		2,578

Income (loss) before income taxes	$	1,563	$	1,302	$	—	$	(570)	$	2,295
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(123)		—		—		—		(123)
Net investment losses (gains) (2)	17		(218)		(5)		2		(204)
Amortization of acquired intangible assets	431		5		—		—		436
Special items
Strategic optimization program	15		4		41		162		222
Integration and transaction-related costs	—		—		—		7		7
(Gain) on sale of businesses	—		(38)		—		—		(38)
(Benefits) associated with litigation matters	—		(17)		—		—		(17)




Pre-tax adjusted income (loss) from operations	$	1,903	$	1,038	$	36	$	(399)	$	2,578

Other segment information
Depreciation and amortization	601		88		2		6		697

(1) Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

(2) Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
Three months ended September 30, 2024
Revenues from external customers	$	51,552	$	11,919	$	137	$	1	$	63,609
Intersegment revenues	1,045		1,279		18		(2,342)
Net investment (loss) income	(142)		142		79		6		85
Total revenues	52,455		13,340		234		(2,335)		63,694
Net investment results from certain equity method investments	—		(177)		—		—		(177)

Special item related to impairment of dividend receivable	182		—		—		—		182
Adjusted revenues	$	52,637	$	13,163	$	234	$	(2,335)	$	63,699
Pharmacy and other service costs	49,768		—
Medical costs	—		9,355
Selling, general and administrative expenses excluding special items	894		2,637
Other segment items (1)
Interest (expense) and other	—		3
Less: Income attributable to noncontrolling interests	99		—
Pre-tax adjusted income (loss) from operations	$	1,876	$	1,174	$	(6)	$	(425)	$	2,619

Income (loss) before income taxes	$	631	$	1,073	$	(10)	$	(502)	$	1,192
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(99)		—		—		—		(99)
Net investment losses (gains) (2)	748		(8)		4		—		744
Amortization of acquired intangible assets	414		22		—		—		436
Special items

Integration and transaction-related costs	—		—		—		77		77
Loss on sale of businesses	—		87		—		—		87


Impairment of dividend receivable	182		—		—		—		182


Pre-tax adjusted income (loss) from operations	$	1,876	$	1,174	$	(6)	$	(425)	$	2,619

Other segment information
Depreciation and amortization	$	544	$	97	$	4	$	5	$	650


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
Nine months ended September 30, 2025
Revenues from external customers	$	169,470	$	31,986	$	260	$	5	$	201,721
Intersegment revenues	2,336		3,901		39		(6,276)
Net investment income	91		376		222		18		707
Total revenues	171,897		36,263		521		(6,253)		202,428
Net investment results from certain equity method investments	—		(272)		—		—		(272)


Adjusted revenues	$	171,897	$	35,991	$	521	$	(6,253)	$	202,156
Pharmacy and other service costs	163,386		—
Medical costs	—		25,446
Selling, general and administrative expenses	3,135		7,132
Other segment items (1)
Interest (expense) and other	(1)		6
Less: Income attributable to noncontrolling interests	342		—
Pre-tax adjusted income (loss) from operations	5,033		3,419		61		(1,192)		7,321

Income (loss) before income taxes	$	4,101	$	3,764	$	(40)	$	(1,861)	$	5,964
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(342)		—		—		—		(342)
Net investment (gains) losses (2)	(67)		(285)		2		2		(348)
Amortization of acquired intangible assets	1,262		18		—		—		1,280
Special items
Strategic optimization program	83		14		99		370		566
Integration and transaction-related costs	—		—		—		297		297
(Gain) on sale of businesses	(4)		(75)		—		—		(79)
(Benefits) associated with litigation matters	—		(17)		—		—		(17)




Pre-tax adjusted income (loss) from operations	$	5,033	$	3,419	$	61	$	(1,192)	$	7,321

Other segment information
Depreciation and amortization	$	1,772	$	252	$	13	$	16	$	2,053

*(1)*Other segment items represent the difference between segment adjusted revenues less significant segment expenses and pre-tax adjusted income (loss) from operations, and they do not represent significant segment items relative to the CODM's review and oversight.

*(2)*Includes Net investment gains/losses as presented in our Consolidated Statements of Income, as well as the Company's share of certain investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting, which are presented within Fees and other revenues in our Consolidated Statements of Income.


(In millions)	Evernorth Health Services		Cigna Healthcare		Other Operations		Corporate and Eliminations		Total
Nine months ended September 30, 2024
Revenues from external customers	$	144,689	$	35,752	$	333	$	2	$	180,776
Intersegment revenues	3,558		3,606		63		(7,227)
Net investment (loss) income	(18)		463		231		20		696
Total revenues	148,229		39,821		627		(7,205)		181,472
Net investment results from certain equity method investments	—		(238)		—		—		(238)
Special item related to impairment of dividend receivable	182		—		—		—		182
Adjusted revenues	$	148,411	$	39,583	$	627	$	(7,205)	$	181,416
Pharmacy and other service costs	140,458		—
Medical costs	—		27,886
Selling, general and administrative expenses	2,825		7,986
Other segment items (1)
Interest (expense) and other	(2)		7
Less: Income attributable to noncontrolling interests	271		—
Pre-tax adjusted income (loss) from operations	4,855		3,718		(4)		(1,269)		7,300

Income (loss) before income taxes	$	1,494	$	3,221	$	(9)	$	(1,446)	$	3,260
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) attributable to noncontrolling interests	(271)		—		—		—		(271)
Net investment losses (2)	2,203		359		5		—		2,567
Amortization of acquired intangible assets	1,247		32		—		—		1,279
Special items

Integration and transaction-related costs	—		—		—		177		177
Loss on sale of businesses	—		106		—		—		106


Impairment of dividend receivable	182		—		—		—		182


Pre-tax adjusted income (loss) from operations	$	4,855	$	3,718	$	(4)	$	(1,269)	$	7,300

Other segment information
Depreciation and amortization	$	1,764	$	334	$	7	$	24	$	2,129

Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. The following table presents these revenues by product, premium and service type:


	Three Months Ended September 30,				Nine Months Ended September 30,
(In millions)	2025		2024		2025		2024
Products (Pharmacy revenues) (ASC 606)
Network revenues	$	32,525	$	27,353	$	91,319	$	76,795
Home delivery and specialty revenues	20,513		18,909		59,424		53,384
Other revenues	3,403		2,990		9,913		8,433
Total Evernorth Health Services	56,441		49,252		160,656		138,612
Other Operations	14		14		41		47
Corporate and eliminations	(401)		(982)		(2,361)		(3,238)
Total Pharmacy revenues	56,054		48,284		158,336		135,421
Insurance premiums (ASC 944)
Cigna Healthcare
U.S. Healthcare
Employer insured	4,705		4,382		14,077		13,125
Medicare Advantage	—		2,110		2,363		6,604
Stop loss	1,908		1,689		5,655		5,022
Individual and Family Plans	788		1,001		2,588		3,016
Other	488		1,203		2,822		3,681
U.S. Healthcare	7,889		10,385		27,505		31,448
International Health	1,047		911		3,051		2,687
Total Cigna Healthcare	8,936		11,296		30,556		34,135
Other Operations	68		122		227		285
Corporate and eliminations	77		18		190		73
Total Premiums	9,081		11,436		30,973		34,493
Services (Fees) (ASC 606) and Other revenues (1)
Evernorth Health Services	3,921		3,345		11,150		9,635
Cigna Healthcare	1,881		1,902		5,331		5,223
Other Operations	—		19		31		64
Corporate and eliminations	(1,422)		(1,377)		(4,100)		(4,060)
Total Fees and other revenues (1)	4,380		3,889		12,412		10,862
Total revenues from external customers	$	69,515	$	63,609	$	201,721	$	180,776

*(1)*Other revenues for the three months ended September 30, 2025 and 2024 were $276 million and $267 million, respectively, and for the nine months ended September 30, 2025 and 2024 were $552 million and $509 million, respectively.

Financial and performance guarantees. Evernorth Health Services may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period, and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid following the end of the annual guarantee period. Historically, adjustments to original estimates have not been material. This guarantee liability was $1.6 billion as of September 30, 2025 and $1.9 billion December 31, 2024.

Previous: Cover and table of contents · Next: Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS